Yarrow

Yarrow is an RTW-incubated biotechnology company focused on developing therapeutics for auto-immune diseases.

Our targets and approaches stem from knowledge and discoveries in human biology, pharmacology, and genetics. Our primary focus is on the discovery and development of safe and efficacious biologics to address significant unmet need and improve patient and caregiver experience. Our lead program is for the treatment of an autoimmune disease with the potential to be the first- and best-in-class disease-modifying therapy in multiple indications. 

Founded
2021
Location
New York, NY
Phase
Preclinical

The need

Autoimmune disorders affect 1 in 10 Americans, making it the third most prevalent disease category after cancer and heart disease.  With more than 80 autoimmune diseases identified, diagnosis can be difficult and treatments unavailable to ease symptoms. Women make up almost 80% of the people with chronic autoimmune conditions.

Mission

Yarrow was founded and incubated by the RTW team in New York and is rooted in the firm’s longstanding expertise and commitment to solving genetic diseases and developing best-in-class therapeutics for cardiovascular, eye, and auto-immune diseases. 

Next milestone

By working closely with the Yarrow team, we strive to expand Yarrow’s internal R&D capabilities, by initiating drug discovery programs as well as in-licensing assets to further capitalize business and team expansion. 

Pipeline

Preclinical
Phase 1
Phase 2
Phase 3
Registrational
Commercial
  • ASO TECHNOLOGY

  • Pre-clinical
  • Phase 1-3
  • Registrational
  • Commercial